Literature summary for 3.4.17.20 extracted from

Koutroubakis, I.E.; Sfiridaki, A.; Tsiolakidou, G.; Coucoutsi, C.; Theodoropoulou, A.; Kouroumalis, E.A.
Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease (2008), Eur. J. Gastroenterol. Hepatol., 20, 912-916.

Search for more literature for 3.4.17.20

Application

Application	Comment	Organism
medicine	TAFI as well as plasminogen activator inhibitor-1 plasma levels in inflammatory bowel disease patients are compared with healthy controls. Mean plasma plasminogen activator inhibitor-1 levels are significantly higher in both ulcerative colitis patients and Crohns disease patients compared with healthy controls. Mean plasma TAFI levels are significantly lower in both ulcerative colitis patients and Crohns disease patients compared with healthy controls. These results suggest an imbalance of fibrinolysis in inflammatory bowel disease patients	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
blood plasma	-	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
TAFI	-	Homo sapiens
thrombin-activatable fibrinolysis inhibitor	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)